Global Vaccine Market Outlook 2020

The pharmaceutical segment has faced diminishing prospects because of
declining research and development productivity, stringent regulatory
activities and generic competition for off patent products. On the contrary,
vaccine segment has developed as highly profitable because of advancements in
genomics and manufacturing technologies as well as increasing demand from
emerging economies.

Meanwhile, continuous efforts have been put in by the biopharmaceutical
companies to create tremendous opportunities for leading players to tap this
market. Besides, vaccines have high entry barrier for generic players and
potential to generate blockbuster sales, which thereby allure the market
players.

The report, "Global Vaccine Market Outlook 2020" provides an extensive
research and in-depth analysis of the current status and future outlook of the
global vaccine market. The market, which stood at US$ 30.5 Billion in 2013, is
expected to grow at a CAGR of around 12% during 2013-2020.

In our report, we have segmented the global vaccine market based on 16
therapeutic categories, and market for each has been forecasted. For each
therapeutic segment, marketed product portfolio, pipeline products along with
recent developments have been analyzed. Followed by this, important
geographies have been highlighted along with their current and future markets
outlook till 2020. The report also covers advanced stage pipeline analysis of
key players, which list down the vaccines already in Phase III trials. Through
this, our analysts have conducted a thorough opportunity assessment in various
therapeutic categories and regions to clearly highlight avenues which offer
maximum opportunities for growth.

In the end, various key players have been enlisted. Our team has analyzed each
company's strengths and weaknesses along with its vaccine portfolio and
pipeline that will help the reader to better position his company
vis-à-vis competition.